Clinical Outcomes after Proton Partial-Breast Radiotherapy for Early-Stage, Hormone Receptor-Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial

被引：3
|
作者：
Choi, I. J. [1 ]
Prabhu, K., Jr. [2 ]
Hartsell, W. F. [3 ]
Sinesi, C. C. [4 ]
Vargas, C. E. [5 ,6 ]
Benda, R. K. [7 ]
Cahlon, O. [8 ]
Chang, A. L. [9 ]
机构：
[1] New York Proton Ctr, New York, NY USA
[2] Procure Proton Therapy Ctr, Oklahoma City, OK USA
[3] Northwestern Med Chicago Proton Ctr, Warrenville, IL USA
[4] Hampton Univ, Proton Therapy Inst, Hampton, VA 23668 USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Mayo Clin Arizona, Dept Radiat Oncol, Phoenix, AZ USA
[7] Boca Raton Reg Hosp, Boca Raton, FL USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] Calif Protons Canc Therapy Ctr, San Diego, CA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2042
引用
收藏
页码：E19 / E19
页数：1
相关论文
共 50 条
  • [31] Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
    Sardesai, Sagar D.
    Kassem, Mahmoud
    Morgan, Evan
    Palettas, Marilly
    Stephens, Julie
    Williams, Nicole Olivia
    Stover, Daniel G.
    Van Deusen, Jeffery
    Wesolowski, Robert
    Lustberg, Maryam B.
    Ramaswamy, Bhuvaneswari
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] INTRAOPERATIVE RADIOTHERAPY IN EARLY-STAGE BREAST CANCER: RESULTS OF THE MONTPELLIER PHASE II TRIAL
    Lemanski, Claire
    Azria, David
    Gourgon-Bourgade, Sophie
    Gutowski, Marian
    Rouanet, Phillippe
    Saint-Aubert, Bernard
    Ailleres, Norbert
    Fenoglietto, Pascal
    Dubois, Jean-Bernard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 698 - 703
  • [33] Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer
    Zhu, Lizhe
    Ma, Nan
    Wang, Bin
    Zhou, Can
    Yan, Yu
    Wang, Ke
    He, Jianjun
    Ren, Yu
    ONCOLOGY LETTERS, 2019, 17 (06) : 5469 - 5480
  • [34] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yan, Yi-Dan
    Fu, Jie
    Gu, Zhi-Chun
    Lu, Jin-Song
    Su, Ying-Jie
    Lin, Hou-Wen
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01) : 184 - 190
  • [35] Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer
    Jerez, Yolanda
    Herrero, Blanca
    Arregui, Marta
    Moron, Blanca
    Martin, Miguel
    Echavarria, Isabel
    FUTURE ONCOLOGY, 2020, 16 (17) : 1165 - 1177
  • [36] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yi-Dan Yan
    Jie Fu
    Zhi-Chun Gu
    Jin-Song Lu
    Ying-Jie Su
    Hou-Wen Lin
    International Journal of Clinical Pharmacy, 2023, 45 : 184 - 190
  • [37] Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer
    Gupta, Tanya
    Purington, Natasha
    Liu, Mina
    Han, Summer
    Sledge, George
    Schapira, Lidia
    Kurian, Allison
    CANCER RESEARCH, 2021, 81 (04)
  • [38] A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases.
    Xu, Jing
    Higgins, Michaela Jane
    Tolaney, Sara M.
    Come, Steven E.
    Smith, Matthew Raymond
    Fornier, Monica N.
    Mahmood, Umar
    Yeap, Beow Y.
    Chabner, Bruce Allan
    Isakoff, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care
    LeVasseur, Nathalie
    Gelmon, Karen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1816 - +
  • [40] Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer
    Nader-Marta, G.
    Waks, A. G.
    Tolaney, S. M.
    Mayer, E. L.
    ESMO OPEN, 2024, 9 (11)
12345